Van Eck Associates Corp Hutchmed (China) LTD Transaction History

Van Eck Associates Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$16.25 - $20.23 $10,806 - $13,452	-665 Reduced 49.85%	669 $12,000
Q3 2023 Nov 08, 2023	BUY	$11.85 - $16.95 $9,290 - $13,288	784 Added 142.55%	1,334 $23,000
Q1 2023 May 03, 2023	SELL	$13.02 - $19.87 $130 - $198	-10 Reduced 1.79%	550 $7,000
Q4 2022 Feb 08, 2023	BUY	$7.65 - $15.51 $1,728 - $3,505	226 Added 67.66%	560 $8,000
Q3 2022 Oct 27, 2022	BUY	$8.63 - $15.52 $1,354 - $2,436	157 Added 88.7%	334 $3,000
Q2 2022 Aug 03, 2022	BUY	$8.59 - $20.77 $824 - $1,993	96 Added 118.52%	177 $2,000
Q3 2021 Nov 03, 2021	BUY	$35.66 - $42.94 $1,640 - $1,975	46 Added 131.43%	81 $3,000
Q2 2021 Aug 10, 2021	BUY	$23.7 - $39.27 $829 - $1,374	35 New	35 $1,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

Stay updated on Van Eck Associates Corp with notifications on news.